🇺🇸 FDA
Patent

US 6803386

Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer

expired A61KA61K31/557A61K31/5575

Quick answer

US patent 6803386 (Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer) held by United Therapeutics Corporation expires Mon Oct 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Oct 12 2004 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/557, A61K31/5575